Javascript must be enabled to continue!
Patient research priorities in melanoma: a national qualitative interview study
View through CrossRef
Abstract
Background
Outcomes for advanced melanoma have improved following the advent of immunotherapy and targeted therapy. This heralds a need for reconsideration of future research agendas. Patients can – and are keen to – help identify and prioritize research topics to ensure future research benefits patients. No previous peer-reviewed research has reported patient research priorities for melanoma.
Objectives
To determine the prioritized research topics of patients with melanoma in England.
Methods
Patients aged ≥ 18 years, diagnosed with melanoma in the past 10 years, were recruited across England by skin cancer charities. Preinterview questionnaires obtained demographic, tumour and treatment information. Semi-structured interviews were conducted where patients were asked what they thought were important topics to research in melanoma. Using a grounded theory approach, transcripts were analysed in an iterative process to identify themes for patient research priorities.
Results
Twenty patients were individually interviewed from eight of nine English regions. Five key themes were identified: (1) ‘Risk factors and prevention of melanoma’ – patients voiced a desire for research into modifiable risk factors and public campaigns to prevent melanoma; (2) ‘Diagnostic delay and misdiagnosis of melanoma’ – patients felt diagnostic delays could be reduced through research to support nonspecialists and integrating technology such as teledermatology or artificial intelligence’; (3) ‘Indications, outcomes, side-effects and interactions of treatments for melanoma’ – novel treatments inspired patients to encourage future research into the indications, outcomes and side-effects of therapeutic options; (4) ‘Optimizing follow-up for melanoma’ – with increased survivorship, research to support the delivery of a personalized approach to follow-up was valued; and (5) ‘Factors that influence survival from melanoma’ – patients prioritized research to accurately predict recurrence and survival based on patient-specific factors.
Conclusions
This is the first peer-reviewed study to report patient research priorities in melanoma. Many of the themes identified align with National Institute for Health and Care Excellence research recommendations. Additionally, novel themes were identified that provide a rationale to develop a James Lind Alliance Priority Setting Partnership for melanoma. If research addresses topics relevant to patients, decision-makers will be equipped to deliver services that meet patient needs.
Oxford University Press (OUP)
Title: Patient research priorities in melanoma: a national qualitative interview study
Description:
Abstract
Background
Outcomes for advanced melanoma have improved following the advent of immunotherapy and targeted therapy.
This heralds a need for reconsideration of future research agendas.
Patients can – and are keen to – help identify and prioritize research topics to ensure future research benefits patients.
No previous peer-reviewed research has reported patient research priorities for melanoma.
Objectives
To determine the prioritized research topics of patients with melanoma in England.
Methods
Patients aged ≥ 18 years, diagnosed with melanoma in the past 10 years, were recruited across England by skin cancer charities.
Preinterview questionnaires obtained demographic, tumour and treatment information.
Semi-structured interviews were conducted where patients were asked what they thought were important topics to research in melanoma.
Using a grounded theory approach, transcripts were analysed in an iterative process to identify themes for patient research priorities.
Results
Twenty patients were individually interviewed from eight of nine English regions.
Five key themes were identified: (1) ‘Risk factors and prevention of melanoma’ – patients voiced a desire for research into modifiable risk factors and public campaigns to prevent melanoma; (2) ‘Diagnostic delay and misdiagnosis of melanoma’ – patients felt diagnostic delays could be reduced through research to support nonspecialists and integrating technology such as teledermatology or artificial intelligence’; (3) ‘Indications, outcomes, side-effects and interactions of treatments for melanoma’ – novel treatments inspired patients to encourage future research into the indications, outcomes and side-effects of therapeutic options; (4) ‘Optimizing follow-up for melanoma’ – with increased survivorship, research to support the delivery of a personalized approach to follow-up was valued; and (5) ‘Factors that influence survival from melanoma’ – patients prioritized research to accurately predict recurrence and survival based on patient-specific factors.
Conclusions
This is the first peer-reviewed study to report patient research priorities in melanoma.
Many of the themes identified align with National Institute for Health and Care Excellence research recommendations.
Additionally, novel themes were identified that provide a rationale to develop a James Lind Alliance Priority Setting Partnership for melanoma.
If research addresses topics relevant to patients, decision-makers will be equipped to deliver services that meet patient needs.
Related Results
Abstract LB163: Germline pathogenic variants in melanoma patients
Abstract LB163: Germline pathogenic variants in melanoma patients
Abstract
Background: The etiology of melanoma has generally been thought to be exposure to UV radiation (sun and sun tanning lamps). However, the percent of melanoma...
Autonomy on Trial
Autonomy on Trial
Photo by CHUTTERSNAP on Unsplash
Abstract
This paper critically examines how US bioethics and health law conceptualize patient autonomy, contrasting the rights-based, individualist...
The Risk of Subsequent Invasive Melanoma after a Primary in Situ or Invasive Melanoma in a High Incidence Country (New Zealand)
The Risk of Subsequent Invasive Melanoma after a Primary in Situ or Invasive Melanoma in a High Incidence Country (New Zealand)
Abstract
Background
Patients with invasive melanoma are at increased risk of developing subsequent invasive melanoma, but the ri...
619. Pharmacokinetic-Pharmacodynamic (PK-PD) Target Attainment Analyses to Support Epetraborole Dose Selection for the Treatment of Patients with Mycobacterium avium Complex (MAC) Lung Disease
619. Pharmacokinetic-Pharmacodynamic (PK-PD) Target Attainment Analyses to Support Epetraborole Dose Selection for the Treatment of Patients with Mycobacterium avium Complex (MAC) Lung Disease
Abstract
Background
Epetraborole (EBO) is an orally available, bacterial leucyl transfer RNA synthetase inhibitor that concentra...
LB2306. Population Pharmacokinetic (PPK), Pharmacokinetic/Pharmacodynamic attainment (PTA), and Clinical Pharmacokinetic/Pharmacodynamic (PK/PD) Analyses for Sulbactam-Durlobactam (SUL-DUR) to Support Dose Selection for the Treatment of Acinetobacter baum
LB2306. Population Pharmacokinetic (PPK), Pharmacokinetic/Pharmacodynamic attainment (PTA), and Clinical Pharmacokinetic/Pharmacodynamic (PK/PD) Analyses for Sulbactam-Durlobactam (SUL-DUR) to Support Dose Selection for the Treatment of Acinetobacter baum
Abstract
Background
SUL-DUR is a β-lactam/β-lactamase inhibitor combination in development for the treatment of ABC infections, ...
Divergent pathways of melanoma development: evidence from a Southern European cohort
Divergent pathways of melanoma development: evidence from a Southern European cohort
Nevus counts in the divergent pathway model of melanoma development have been studied mainly in patients in Australia. Our aim was to compare nevus counts and the melanoma subtype ...
593. Population Pharmacokinetic Model Development for Epetraborole and Mycobacterium avium Complex (MAC) Lung Disease Patients Using Data from Phase 1 and 2 Studies
593. Population Pharmacokinetic Model Development for Epetraborole and Mycobacterium avium Complex (MAC) Lung Disease Patients Using Data from Phase 1 and 2 Studies
Abstract
Background
Epetraborole (EBO), an orally available bacterial leucyl transfer RNA synthetase inhibitor with potent activ...
Precursors of skin melanoma (melanoma-sensitive nevi)
Precursors of skin melanoma (melanoma-sensitive nevi)
Interest in melanoma precursors, or melanoma-sensitive skin nevi, has not lost its relevance for many years due to the steady increase of skin melanoma morbidity in recent decades ...

